BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Lymphoma AND AXIN1, LA16c-314G4_3, 8312, ENSG00000103126, O15169, AXIN, MGC52315 AND Clinical Outcome
790 results:

  • 1. Validation of genes for H-ARS severity prediction in leukemia patients - interspecies comparison, challenges, and promises.
    Schwanke D; Valente M; Ostheim P; Schüle S; Bobyk L; Drouet M; Riccobono D; Magné N; Daguenet E; Stewart SJ; Muhtadi R; Port M; Abend M
    Int J Radiat Biol; 2024; 100(4):527-540. PubMed ID: 38227483
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Non-IG::MYC in diffuse large B-cell lymphoma confers variable genomic configurations and MYC transactivation potential.
    Zhang C; Stelloo E; Barrans S; Cucco F; Jiang D; Tzioni MM; Chen Z; Li Y; Swennenhuis JF; Makker J; Rásó-Barnett L; Liu H; El-Daly H; Soilleux E; Shah N; Nagumantry SK; Kyaw M; Prahladan MP; Tooze R; Westhead DR; Feitsma H; Davies AJ; Burton C; Johnson PWM; Du MQ
    Leukemia; 2024 Mar; 38(3):621-629. PubMed ID: 38184753
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. The fifth edition of the WHO classification of mature B-cell neoplasms: open questions for research.
    Coupland SE; Du MQ; Ferry JA; de Jong D; Khoury JD; Leoncini L; Naresh KN; Ott G; Siebert R; Xerri L;
    J Pathol; 2024 Mar; 262(3):255-270. PubMed ID: 38180354
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Biological signatures of the International Prognostic Index in diffuse large B-cell lymphoma.
    Wang Y; Shi Q; Shi ZY; Tian S; Zhang MC; Shen R; Fu D; Dong L; Yi HM; Ouyang BS; Mu RJ; Cheng S; Wang L; Xu PP; Zhao WL
    Blood Adv; 2024 Apr; 8(7):1587-1599. PubMed ID: 38170757
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. RNA-seq-based miRNA signature as an independent predictor of relapse in pediatric B-cell acute lymphoblastic leukemia.
    Kubota H; Ueno H; Tasaka K; Isobe T; Saida S; Kato I; Umeda K; Hiwatari M; Hasegawa D; Imamura T; Kakiuchi N; Nannya Y; Ogawa S; Hiramatsu H; Takita J
    Blood Adv; 2024 Mar; 8(5):1258-1271. PubMed ID: 38127276
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Evaluation of the cachexia index using a bioelectrical impedance analysis in elderly patients with non-Hodgkin's lymphoma: A single-center prospective study.
    Okubo S; Shinmura K; Kadota S; Nakayasu M; Kurosawa S; Nakayama H; Sakurai A; Ito C; Aisa Y; Nakazato T
    Ann Hematol; 2024 Mar; 103(3):823-831. PubMed ID: 38010408
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. clinical and prognostic role of sarcopenia based on masticatory muscle index on MR images in patients with extranodal natural killer/T cell lymphoma, nasal type.
    Xu T; Li Y; Liu Y; Ning B; Wu H; Wei Y
    Ann Hematol; 2023 Dec; 102(12):3521-3532. PubMed ID: 37702822
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. MYC protein is a high-risk factor in mantle cell lymphoma and identifies cases beyond morphology, proliferation and
    Rodrigues JM; Hollander P; Schmidt L; Gkika E; Razmara M; Kumar D; Geisler C; Grønbæk K; Eskelund CW; Räty R; Kolstad A; Sundström C; Glimelius I; Porwit A; Jerkeman M; Ek S
    Haematologica; 2024 Apr; 109(4):1171-1183. PubMed ID: 37646663
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Selinexor With Anti-PD-1 Antibody as a Potentially Effective Regimen for Patients With Natural Killer/T-Cell lymphoma Failing Prior L-Asparaginase and PD-1 Blockade.
    Tao R; Liu C; Zhang W; Zhu Y; Ma Y; Hao S
    Oncologist; 2024 Jan; 29(1):e90-e96. PubMed ID: 37616529
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. PersonALL: a genetic scoring guide for personalized risk assessment in pediatric B-cell precursor acute lymphoblastic leukemia.
    Bedics G; Egyed B; Kotmayer L; Benard-Slagter A; de Groot K; Bekő A; Hegyi LL; Bátai B; Krizsán S; Kriván G; Erdélyi DJ; Müller J; Haltrich I; Kajtár B; Pajor L; Vojcek Á; Ottóffy G; Ujfalusi A; Szegedi I; Tiszlavicz LG; Bartyik K; Csanádi K; Péter G; Simon R; Hauser P; Kelemen Á; Sebestyén E; Jakab Z; Matolcsy A; Kiss C; Kovács G; Savola S; Bödör C; Alpár D
    Br J Cancer; 2023 Aug; 129(3):455-465. PubMed ID: 37340093
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Leukapheresis and Tisagenlecleucel Manufacturing outcomes in Patients Age <3 Years with Relapsed/Refractory Acute Lymphoblastic Leukemia.
    Fong D; Tiwari R; Acker C; Clough L; Willert J
    Transplant Cell Ther; 2023 Sep; 29(9):579.e1-579.e10. PubMed ID: 37311511
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Blastoid and Pleomorphic Mantle Cell lymphoma Demonstrate Distinct Clinicopathologic and Genetic Features.
    Khanlari M; Mo H; Kim DH; Sakhdari A; Young KH; Jain P; Wang M; Li S; Kanagal-Shamanna R; Miranda RN; Vega F; Medeiros LJ; Ok CY
    Am J Surg Pathol; 2023 Aug; 47(8):849-858. PubMed ID: 37288826
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. clinical significance of plasma PD-L1
    Xu P; Liu J; Chen H; Shang L; Wang F; Zhu Y; Guo Y; Li F; Yan F; Xie X; Li L; Gu W; Lin Y
    Ann Hematol; 2023 Sep; 102(9):2435-2444. PubMed ID: 37162517
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. clinical Analysis of Pediatric T-Cell Acute Lymphoblastic Leukemia Using the MRD-Oriented Strategy System.
    Xue YJ; Wang Y; Lu AD; Jia YP; Zuo YX; Ding MM; Zeng HM; Zhang LP
    Clin Lymphoma Myeloma Leuk; 2023 Jul; 23(7):477-483. PubMed ID: 37080879
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Reinforcement of cell-mediated immunity driven by tumor-associated Epstein-Barr virus (EBV)-specific T cells during targeted B-cell therapy with rituximab.
    Tischer-Zimmermann S; Bonifacius A; Santamorena MM; Mausberg P; Stoll S; Döring M; Kalinke U; Blasczyk R; Maecker-Kolhoff B; Eiz-Vesper B
    Front Immunol; 2023; 14():878953. PubMed ID: 37033971
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Real-world data from yttrium-90 ibritumomab tiuxetan treatment of relapsed or refractory indolent B-cell non-Hodgkin's lymphoma: J3Zi Study.
    Choi I; Okada M; Ito T
    Ann Hematol; 2023 May; 102(5):1149-1158. PubMed ID: 36995403
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. The prognostic value of splenic abnormalities in pretreatment
    Wang S; Ju H; Bai Y; Wang L; Ding Q; Li P; Jiang X; Lin X
    Clin Radiol; 2023 May; 78(5):375-380. PubMed ID: 36805286
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. [The impact of donor-to-recipient gender compatibility on outcomes of haploid hematopoietic stem cell transplantation in patients with hematological malignancies].
    Hu SS; Wu YB; Zhu PP; Shi JM; Yu J; Zhao YM; Lai XY; Liu LZ; Fu HR; Huang H; Luo Y
    Zhonghua Xue Ye Xue Za Zhi; 2022 Dec; 43(12):992-1002. PubMed ID: 36709104
    [No Abstract]    [Full Text] [Related]  

  • 19. Novel reconstruction method by mega-prosthesis wrapped with vancomycin-containing cement after resection of malignancies.
    Hashimoto K; Nishimura S; Shinyashiki Y; Ito T; Kakinoki R; Akagi M
    Medicine (Baltimore); 2022 Dec; 101(48):e31547. PubMed ID: 36482578
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Bendamustine Plus Rituximab for Mantle Cell lymphoma: A Korean, Multicenter Retrospective Analysis.
    Yi JH; Kim SJ; Lee JO; Lee GW; Kwak JY; Eom HS; Jo JC; Choi YS; Oh SY; Kim WS
    Anticancer Res; 2022 Dec; 42(12):6083-6089. PubMed ID: 36456154
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 40.